Ani pharmaceuticals announces fda acceptance of purified cortrophin® gel supplemental new drug application for multiple indications including multiple sclerosis, rheumatoid arthritis, and nephrotic syndrome

Baudette, minn.--(business wire)--ani pharmaceuticals, inc. (“ani” or the “company”) (nasdaq:anip) today announced that the company's supplemental new drug application (“snda”) for purified cortrophin® gel (“cortrophin gel”) has been accepted by the u.s. food and drug administration (“fda”) for review. “fda's acceptance of our snda for cortrophin gel marks a significant milestone for ani. with a pdufa target action date of october 29, 2021, we are one step closer to bringing a much-needed produ
ANIP Ratings Summary
ANIP Quant Ranking